IMMUNIZATIONTO RITUXIMAB IS MORE FREQUENT IN AUTOIMMUNE SYSTEMIC AUTOIMMUNE DISEASES THAN IN RHEUMATOID ARTHRITIS AND MAY BE MANAGED BY SWITCHING FROM RITUXIMAB TO OFATUMUMAB

被引：0
|
作者：
Combier, Alice [1 ]
Nocturne, Gaetane [1 ]
Henry, Julien [1 ]
Belkhir, Rakiba [1 ]
Pavy, Stephane [1 ]
Mariette, Xavier [1 ]
Seror, Raphaele [1 ]
机构：
[1] Bicetre Hosp, AP HP, Rheumatol, Le Kremlin Bicetre, France
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2019年 / 78卷
关键词：
D O I：
10.1136/annrheumdis-2019-eular.3343
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0462
引用
收藏
页码：1695 / 1695
页数：1
相关论文
共 50 条
  • [41] REAL-WORLD EXPERIENCE OF SWITCHING FROM ORIGINATOR TO BIOSIMILAR RITUXIMAB IN RHEUMATOID ARTHRITIS
    Melville, A.
    Yusof, M. Y. Md
    Fitton, J.
    Bailey, L.
    Emery, P.
    Buch, M. H.
    Dass, S.
    Saleem, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 299 - 300
  • [42] Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries
    Mariette, Xavier
    Gottenberg, Jacques-Eric
    Ravaud, Philippe
    Combe, Bernard
    RHEUMATOLOGY, 2011, 50 (01) : 222 - 229
  • [43] Development of germline NGS Panel for autoimmune diseases: Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Systemic Sclerosis
    Solomadin, Maxim
    Baigenzhin, Abay
    Zaripova, Lina
    Kozina, Larissa
    Boltanova, Alyona
    Iglikov, Talgat
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2024, 32 : 1183 - 1184
  • [44] EFFICACY AND TOLERABILITY OF B CELL DEPLETION THERAPY WITH RITUXIMAB IN PATIENTS WITH SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES: THE EXPERIENCE FROM ONE CENTER
    Ananyeva, L.
    Soloviev, S.
    Beketova, T.
    Vasiliev, V.
    Antelava, O.
    Aleksandrova, E.
    Koneva, O.
    Tsanyan, M.
    Desinova, O.
    Logvinenko, O.
    Volkov, A.
    Sergeeva-Khelkovskaya, A.
    Novikov, A.
    Nasonov, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1118 - 1118
  • [45] Thyroid hormone autoantibodies in primary Sjogren syndrome and rheumatoid arthritis are more prevalent than in autoimmune thyroid disease, becoming progressively more frequent in these diseases (vol 25, pg 447, 2002)
    Ruggeri, RM
    Galletti, M
    Mandolfino, MG
    Aragona, P
    Bartolone, S
    Giorgianni, G
    Alesci, D
    Trimarchi, F
    Benvenga, S
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2002, 25 (07) : v - v
  • [46] Effectiveness and Safety Data in Rheumatoid Arthritis Patients after Switching from Originator Rituximab to Biosimilar Rituximab (CT-P10)
    Ekin, Ali
    Misirci, Salim
    Lermi, Nihal
    Kutlu, Nagehan Dik
    Coskun, Belkis Nihan
    Yagiz, Burcu
    Dalkilic, Ediz
    Pehlivan, Yavuz
    AKTUELLE RHEUMATOLOGIE, 2025, 50 (01) : 71 - 82
  • [47] COMPARISON BETWEEN RITUXIMAB ORIGINATOR THERAPY AND ITS BIOSIMILAR IN THE INCIDENCE OF LATE-ONSET NEUTROPENIA IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS AND OTHER AUTOIMMUNE DISEASES
    Ahmad, M. M.
    Mcrorie, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1134 - 1134
  • [48] Burden of Cardiovascular Disease in Autoimmune Rheumatic Diseases: "The Heart in Systemic Lupus Erythematosus and Rheumatoid Arthritis"
    Corrales, Nicole
    Mayor, Viviana
    Montealegre, Steven
    UNIVERSITAS MEDICA, 2023, 64 (02): : 1 - 12
  • [49] Tocilizumab for the Treatment of Rheumatoid Arthritis and Other Systemic Autoimmune Diseases: Current Perspectives and Future Directions
    Ogata, Atsushi
    Tanaka, Toshio
    INTERNATIONAL JOURNAL OF RHEUMATOLOGY, 2012, 2012
  • [50] Biosimulations predict that rituximab is more efficacious than other standards of care in rheumatoid arthritis patients with severe disease
    Kretsos, Kosmas
    Young, Daniel L.
    Whiting, Chan C.
    Kudrycki, Katherine
    Kellermann, Sirid-Aimee
    Derfanoux, Nadine A.
    CLINICAL IMMUNOLOGY, 2007, 123 : S91 - S91
12345